Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genetics Institute

Executive Summary

Reaches agreement-in-principle with European erythropoietin licensee Boehringer Mannheim to settle a contract dispute related to the manufacture of EPO for Boehringer during 1989, valued at$13 mil. Boehringer has agreed to accept a portion of the EPO it had previously disputed, and Genetics Institute has agreed to replace in fiscal 1991 some of the disputed material with product manufactured via a different process. Last month, Boehringer Mannheim received a favorable recommendation for EPO marketing in Europe from the EC's Committee for Proprietary Medicinal Products. The company says it expects to launch EPO within the next several months.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel